{"DataElement":{"publicId":"6586581","version":"1","preferredName":"Iris Uveal Melanoma AJCC Edition 8 Clinical Regional Lymph Node N Category","preferredDefinition":"Extent of the regional lymph node involvement for iris melanoma based on evidence obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter), using AJCC Ed. 8 criteria.","longName":"IRIS_AJC8_CLN_N_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6584936","version":"1","preferredName":"Iris Uveal Melanoma Clinical N Category","preferredDefinition":"The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber._A melanoma derived from melanocytes of the uveal tract.  It is the most common primary intraocular tumor in the United States and Western Europe.  Similar to melanoma of the skin, it is rare in Africa and Asia.  Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound.  Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection.  Recent treatments also include radiotherapy or photo coagulation.  Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types.  The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","longName":"6584932v1.0:2428496v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6584932","version":"1","preferredName":"Iris Uveal Melanoma","preferredDefinition":"The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.:A melanoma derived from melanocytes of the uveal tract.  It is the most common primary intraocular tumor in the United States and Western Europe.  Similar to melanoma of the skin, it is rare in Africa and Asia.  Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound.  Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection.  Recent treatments also include radiotherapy or photo coagulation.  Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types.  The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.","longName":"C12737:C7712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iris","conceptCode":"C12737","definition":"The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Uveal Melanoma","conceptCode":"C7712","definition":"A melanoma derived from melanocytes of the uveal tract.  It is the most common primary intraocular tumor in the United States and Western Europe.  Similar to melanoma of the skin, it is rare in Africa and Asia.  Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound.  Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection.  Recent treatments also include radiotherapy or photo coagulation.  Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types.  The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CB01ACC-61E5-4C0A-E053-F662850AF5D4","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-10","modifiedBy":"ONEDATA","dateModified":"2018-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2428496","version":"1","preferredName":"Clinical N Stage","preferredDefinition":"Having to do with the examination and treatment of patients.:One criteria of the TMN staging system. N refers to the extent of lymph node involvement.","longName":"C25398:C25580","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"053C2A34-0888-693F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-11","modifiedBy":"ONEDATA","dateModified":"2005-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7CB02521-8CBD-4C7C-E053-F662850A4CB3","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-10","modifiedBy":"TAYLORT","dateModified":"2019-09-06","changeDescription":"9-6-19 TMT released per MC.; 12/10/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6586462","version":"1","preferredName":"Iris Uveal Melanoma American Joint Committee on Cancer Edition 8 N Category","preferredDefinition":"The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber._A finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to malignant melanoma of the iris, ciliary body, and choroid. Cutaneous melanoma metastatic to the iris, ciliary body, and choroid is staged according to the classification for melanoma of the skin and secondary intraocular extension of conjunctival melanoma is staged according to the classification for conjunctival melanoma. (from AJCC 8th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._A grouping of items based on some commonality or by user defined characteristics._One criteria of the TNM staging system. N refers to the extent of lymph node involvement._A grouping of items based on some commonality or by user defined characteristics.","longName":"6586462v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"N1a","valueDescription":"Uveal Melanoma pN1a TNM Finding v8","ValueMeaning":{"publicId":"6586464","version":"1","preferredName":"Uveal Melanoma pN1a TNM Finding v8","longName":"6586464","preferredDefinition":"Uveal melanoma with metastasis in one or more regional lymph node(s). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uveal Melanoma pN1a TNM Finding v8","conceptCode":"C140654","definition":"Uveal melanoma with metastasis in one or more regional lymph node(s). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CB23D8E-4A4A-022D-E053-F662850ABCBD","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-10","modifiedBy":"ONEDATA","dateModified":"2018-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CB23D8E-4A63-022D-E053-F662850ABCBD","beginDate":"2018-12-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-10","modifiedBy":"ONEDATA","dateModified":"2018-12-10","deletedIndicator":"No"},{"value":"N1","valueDescription":"Uveal Melanoma pN1 TNM Finding v8","ValueMeaning":{"publicId":"6586466","version":"1","preferredName":"Uveal Melanoma pN1 TNM Finding v8","longName":"6586466","preferredDefinition":"Uveal melanoma with regional lymph node metastasis or discrete tumor deposits in the orbit. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uveal Melanoma pN1 TNM Finding v8","conceptCode":"C140653","definition":"Uveal melanoma with regional lymph node metastasis or discrete tumor deposits in the orbit. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CB23D8E-4A70-022D-E053-F662850ABCBD","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-10","modifiedBy":"ONEDATA","dateModified":"2018-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CB23D8E-4A89-022D-E053-F662850ABCBD","beginDate":"2018-12-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-10","modifiedBy":"ONEDATA","dateModified":"2018-12-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6586461","version":"1","preferredName":"Iris Uveal Melanoma TNM Finding v8 American Joint Committee on Cancer N Category Category","preferredDefinition":"The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.:A finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to malignant melanoma of the iris, ciliary body, and choroid. Cutaneous melanoma metastatic to the iris, ciliary body, and choroid is staged according to the classification for melanoma of the skin and secondary intraocular extension of conjunctival melanoma is staged according to the classification for conjunctival melanoma. (from AJCC 8th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system. N refers to the extent of lymph node involvement.:A grouping of items based on some commonality or by user defined characteristics.","longName":"6586461v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iris","conceptCode":"C12737","definition":"The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Uveal Melanoma TNM Finding v8","conceptCode":"C140603","definition":"A finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to malignant melanoma of the iris, ciliary body, and choroid. Cutaneous melanoma metastatic to the iris, ciliary body, and choroid is staged according to the classification for melanoma of the skin and secondary intraocular extension of conjunctival melanoma is staged according to the classification for conjunctival melanoma. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CB23D8E-4A1D-022D-E053-F662850ABCBD","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-10","modifiedBy":"ONEDATA","dateModified":"2018-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CB23D8E-4A2E-022D-E053-F662850ABCBD","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-10","modifiedBy":"TAYLORT","dateModified":"2019-09-06","changeDescription":"9-6-19 TMT released per MC.; 12/10/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6581919","version":"1","longName":"Uveal","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Clinical N category","type":"Preferred Question Text","description":"Clinical N category","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CB2BF37-F354-065B-E053-F662850AF8C0","latestVersionIndicator":"Yes","beginDate":"2018-12-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-11","modifiedBy":"TAYLORT","dateModified":"2019-09-06","changeDescription":"9-6-19 TMT released per MC.; 12/11/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}